Agreement includes a no-later-than July 9, 2015 launch
This Phase I/II clinical trial is designed to evaluate the safety and efficacy of a combination of MK-3475 and pazopanib
Continuous Glucose Monitoring (CGM) Market will Reach $568.5 Million Globally by 2020 - Allied Market Research
PORTLAND, Oregon, December 17, 2013 /PRNewswire/ --
According to the new market research report titled "Continuous Glucose Monitoring Market (CGM Systems, Application, Diabetic Type, and Adoption by Age Group) - Current Trends, Size, Share, Industry Analysis, Competitive Intelligence, Growth, Opportunities and Global Forecasts, 2012 - 2020" by Allied Market Research, the global continuous glucose monitoring (CGM) market is projected to reach $568.5 million by 2020...
Boston Scientific Announces CE Mark Approval And First Implants Of Its Next-Generation X4 Quadripolar CRT-D Systems
NATICK, Mass., Dec. 17, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval of its X4 line of quadripolar CRT-D systems, including the AUTOGEN™ X4, DYNAGEN™ X4, and INOGEN™ X4 cardiac resynchronization therapy defibrillators (CRT-Ds), a suite of ACUITY™ X4 quadripolar LV leads and the ACUITY™ PRO lead delivery system. The company's latest devices to treat heart failure and sudden cardiac arrest are designed to advance patient...
Corgenix Announces Filing of 510(k) Premarket Notification for FDA Clearance of TxBCardio™ Assay
Filing is first under Corgenix Medical - Randox Laboratories co-development agreement
DENVER, Dec. 16, 2013--(BUSINESS WIRE)--Corgenix Medical Corporation (OTC BB: CONX.OB) announced today that in collaboration with Randox Laboratories, the first premarket notification has been filed with the U.S. Food and Drug Administration pursuant to Section 510(k) of the U.S. Federal Food, Drug and Cosmetic Act for the TxBCardio™ immunoturbidimetric (IT) assay.
“Along with our...
Financial details were not disclosed
Almiral: Provides additional geographic and business diversification and gives access to the largest dermatology market globally
Trial shows dabigatran non-inferior to warfarin in preventing recurrent DVT and/or PE and related death, with a reduction in major or clinically relevant non-major bleeding
Study findings indicate that treatment with ACEIs/ARBs in patients with stable hypertension and advanced CKD was associated with a lower risk for long-term dialysis or death by 6 percent
Sucampo also plans to evaluate the long-term safety of lubiprostone in these populations through two open-label extension studies